TABLE 2.

Examples of the use of TWEAK- and Fn14 antagonists in preclinical disease models.

Antagonist	Disease model	Effect	References
Fn14-Fc	SLE developing sanroque mice	Less germinal center formation	Min et al. (2016)
Fn14-Fc	ApoE −/− mice	Smaller, fewer and less fibrotic atherosclerotic plaques	Schapira et al. (2009)
Fn14-Fc	Middle cerebral artery occlusion in mice	Reduced infarct volume Reduced cerebral edema Improved motor activity	Yepes et al. (2005), Zhang et al. (2007)
Fn14-Fc	β-glucan–induced arthritis in SKG mice	Reduced disease score	Park et al. (2017)
Anti-TWEAK	Autosomal dominant polycystic kidney disease	Improved renal function Improved survival	Cordido et al. (2021)
Anti-TWEAK (P2D10)	ApoE −/− mice	Reduced atherosclerotic burden Delayed plaque progression	Fernández-Laso et al. (2017)
Anti-Fn14 18D1-dead	Acute graft-versus-host disease	Reduced intestinal cell death Improved survival	Chopra et al. (2015)
Anti-Fn14 18D1-dead	Intraportal injection xenotransplant model of HCT116 metastasis	Reduced metastasis Improved survival	Trebing et al. (2014)
Anti-Fn14 ITEM-2	Renal ischemia reperfusion injury	Reduced accumulation of neutrophils and macrophages Less tubular cell apoptosis. Prolonged survival	Hotta et al. (2011)
Anti-TWEAK (P5G9)	Chronic graft-versus-host disease-induced lupus	Reduced cytokine/chemokine production and reduced proteinuria	Zhao et al. (2007)
Anti-TWEAK (MTW-1)	Collagen-induced arthritis	Reduced disease score	Kamata et al. (2006)
Anti-TWEAK (P5G9)	Collagen-induced arthritis	Reduced disease score and less synovial angiogenesis	Perper et al. (2006)